These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
701 related articles for article (PubMed ID: 33957110)
1. Translational investigation of electrophysiology in hypertrophic cardiomyopathy. Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110 [TBL] [Abstract][Full Text] [Related]
2. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226 [TBL] [Abstract][Full Text] [Related]
3. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice. Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637 [TBL] [Abstract][Full Text] [Related]
4. Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human Pioner JM; Vitale G; Steczina S; Langione M; Margara F; Santini L; Giardini F; Lazzeri E; Piroddi N; Scellini B; Palandri C; Schuldt M; Spinelli V; Girolami F; Mazzarotto F; van der Velden J; Cerbai E; Tesi C; Olivotto I; Bueno-Orovio A; Sacconi L; Coppini R; Ferrantini C; Regnier M; Poggesi C Circ Res; 2023 Mar; 132(5):628-644. PubMed ID: 36744470 [TBL] [Abstract][Full Text] [Related]
5. Remodeling of repolarization and arrhythmia susceptibility in a myosin-binding protein C knockout mouse model. Toib A; Zhang C; Borghetti G; Zhang X; Wallner M; Yang Y; Troupes CD; Kubo H; Sharp TE; Feldsott E; Berretta RM; Zalavadia N; Trappanese DM; Harper S; Gross P; Chen X; Mohsin S; Houser SR Am J Physiol Heart Circ Physiol; 2017 Sep; 313(3):H620-H630. PubMed ID: 28646025 [TBL] [Abstract][Full Text] [Related]
6. Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes. Wang L; Kim K; Parikh S; Cadar AG; Bersell KR; He H; Pinto JR; Kryshtal DO; Knollmann BC J Mol Cell Cardiol; 2018 Jan; 114():320-327. PubMed ID: 29217433 [TBL] [Abstract][Full Text] [Related]
7. Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue. Dutsch A; Wijnker PJM; Schlossarek S; Friedrich FW; Krämer E; Braren I; Hirt MN; Brenière-Letuffe D; Rhoden A; Mannhardt I; Eschenhagen T; Carrier L; Mearini G Sci Rep; 2019 Dec; 9(1):18152. PubMed ID: 31796859 [TBL] [Abstract][Full Text] [Related]
8. Selective phosphorylation of PKA targets after β-adrenergic receptor stimulation impairs myofilament function in Mybpc3-targeted HCM mouse model. Najafi A; Sequeira V; Helmes M; Bollen IA; Goebel M; Regan JA; Carrier L; Kuster DW; Van Der Velden J Cardiovasc Res; 2016 May; 110(2):200-14. PubMed ID: 26825555 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue. Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529 [TBL] [Abstract][Full Text] [Related]
10. Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice. Najafi A; Schlossarek S; van Deel ED; van den Heuvel N; Güçlü A; Goebel M; Kuster DW; Carrier L; van der Velden J Pflugers Arch; 2015 Jun; 467(6):1303-17. PubMed ID: 25010737 [TBL] [Abstract][Full Text] [Related]
11. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. Fraysse B; Weinberger F; Bardswell SC; Cuello F; Vignier N; Geertz B; Starbatty J; Krämer E; Coirault C; Eschenhagen T; Kentish JC; Avkiran M; Carrier L J Mol Cell Cardiol; 2012 Jun; 52(6):1299-307. PubMed ID: 22465693 [TBL] [Abstract][Full Text] [Related]
12. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes. Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529 [TBL] [Abstract][Full Text] [Related]
13. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice. Barefield D; Kumar M; Gorham J; Seidman JG; Seidman CE; de Tombe PP; Sadayappan S J Mol Cell Cardiol; 2015 Feb; 79():234-43. PubMed ID: 25463273 [TBL] [Abstract][Full Text] [Related]
14. Ouabain worsens diastolic sarcomere length in myocytes from a cardiomyopathy mouse model. Düsener S; Flenner F; Maack C; Kohlhaas M; Bay J; Carrier L; Friedrich FW Eur J Pharmacol; 2021 Aug; 904():174170. PubMed ID: 33984298 [TBL] [Abstract][Full Text] [Related]